The Groundbreaking Series Features Engaging Conversations with People Living with HIV, Advocates and Medical Experts Striving Toward the Shared Goal of Ending HIV
“The Cure Chronicles,” an innovative video series launched by Maryland biotechnology company, American Gene Technologies, is the winner of the third annual BioBuzz Media Award. American Gene Technologies (AGT™) is developing gene therapy technology to combat HIV, and “The Cure Chronicles” takes a deep look into what it means to live with the disease. In the series, AGT’s CEO, Jeff Galvin, interviews HIV advocates and experts – including authors, comedians, doctors, community leaders, and filmmakers – most of whom are living with their own diagnoses.
“We developed The Cure Chronicles because we wanted people to hear directly from those most impacted by HIV, as well as people who are making a difference in this space,” said Galvin. “Our hope is that this series helps break down the stigma that people often face when living with HIV.”
With nineteen episodes released to date, “The Cure Chronicles” features intimate conversations that touch on the many ways that people navigate their diagnosis – and the extraordinary paths it leads them on. Most have gone on to become advocates and educators about HIV, through comedy, film, social media, books, or by working directly with others who are living with HIV. The series also highlights medical experts that are at the forefront of HIV treatment and research.
This approach is clearly resonating: the BioBuzz Media Award, which honors a media campaign that has “successfully engaged, informed, and connected people within scientific communities,” is a people’s choice award. According to BioBuzz, “This award honors a media campaign that most aligns with our own mission; ‘to create exceptional experiences that better connect people and employers and foster a stronger regional ecosystem.”
Watch The Cure Chronicles here.
About American Gene Technologies
American Gene Technologies is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people's lives through genetic medicines that rid the body of disease. Safety and durability data from American Gene Technologies’ Phase 1 HIV gene therapy clinical trial is published in the Frontiers in Medicine journal and a final report is being prepared for regulatory submission. In addition, the company has been granted four patents for the technology used to make AGT103-T and 11 patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. American Gene Technologies has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.
American Gene Technologies